NCT01397097 - LCS12 vs. ENG Subdermal Implant (Nexplanon) Discontinuation Rate Study | Biotech Hunter

Enrollment

766

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

June 30, 2013

Study Completion Date

April 30, 2015

Conditions

Contraception

Interventions

DRUG

LNG-IUS (BAY 86-5028)

LCS12 insertion will occur at randomization visit (Visit 2). Duration of study treatment is 12 months with an follow-up extension for up to 3 years

DRUG

68 mg etonorgestrel implant for subdermal use (Nexplanon)

Implant insertion will occur at randomization visit (Visit 2). Duration of study treatment is 12 months, may be continued up to 3 years under standard care.

Trial Locations (43)

1400

Ski

2031

Ashfield

Sydney

2403

Elverum

3053

Parkville

5006

North Adelaide

5353

Straume

5515

Haugesund

6009

Nedlands

7014

Trondheim

13005

Marseille

20100

Turku

20540

Turku

21800

Quetigny

33000

Bordeaux

33014

Tampereen Yliopisto

33100

Tampere

51092

Reims

59113

Seclin

64200

Biarritz

67300

Schiltigheim

70110

Kuopio

75185

Uppsala

02100

Espoo

00100

Helsinki

00120

Helsinki

00260

Helsinki

67 000

Strasbourg

411 18

Gothenburg

416 64

Gothenburg

582 25

Linköping

972 33

Luleå

205 02

Malmo

217 44

Malmo

701 85

Örebro

118 83

Stockholm

171 76

Stockholm

CB5 8DT

Cambridge

SW10 9NH

London

S1 2PJ

Sheffield

LS2 9AE

Leeds

L20 5DQ

Liverpool

W12 0HS

London